These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 15585396)

  • 1. Caspase-3 drives apoptosis in pancreatic cancer cells after treatment with gemcitabine.
    Chandler NM; Canete JJ; Callery MP
    J Gastrointest Surg; 2004 Dec; 8(8):1072-8. PubMed ID: 15585396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mucin production determines sensitivity to bortezomib and gemcitabine in pancreatic cancer cells.
    Wissniowski TT; Meister S; Hahn EG; Kalden JR; Voll R; Ocker M
    Int J Oncol; 2012 May; 40(5):1581-9. PubMed ID: 22266985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of the proteasome inhibitor bortezomib on gene expression profiles of pancreatic cancer cells.
    Tang ZY; Wu YL; Gao SL; Shen HW
    J Surg Res; 2008 Mar; 145(1):111-23. PubMed ID: 17714734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome.
    Bold RJ; Virudachalam S; McConkey DJ
    J Surg Res; 2001 Sep; 100(1):11-7. PubMed ID: 11516199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancing apoptosis and overcoming resistance of gemcitabine in pancreatic cancer with bortezomib: a role of death-associated protein kinase-related apoptosis-inducing protein kinase 1.
    Guo Q; Chen Y; Wu Y
    Tumori; 2009; 95(6):796-803. PubMed ID: 20210246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gemcitabine-mediated apoptosis is associated with increased CD95 surface expression but is not inhibited by DN-FADD in Colo357 pancreatic cancer cells.
    Christgen M; Schniewind B; Jueschke A; Ungefroren H; Kalthoff H
    Cancer Lett; 2005 Sep; 227(2):193-200. PubMed ID: 16112422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer.
    Shah SA; Potter MW; McDade TP; Ricciardi R; Perugini RA; Elliott PJ; Adams J; Callery MP
    J Cell Biochem; 2001 Apr 2-27; 82(1):110-22. PubMed ID: 11400168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proteasome inhibition sensitizes non-small-cell lung cancer to gemcitabine-induced apoptosis.
    Denlinger CE; Rundall BK; Keller MD; Jones DR
    Ann Thorac Surg; 2004 Oct; 78(4):1207-14; discussion 1207-14. PubMed ID: 15464472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of proliferation by omega-3 fatty acids in chemoresistant pancreatic cancer cells.
    Hering J; Garrean S; Dekoj TR; Razzak A; Saied A; Trevino J; Babcock TA; Espat NJ
    Ann Surg Oncol; 2007 Dec; 14(12):3620-8. PubMed ID: 17896154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Caspase activation is required for gemcitabine activity in multiple myeloma cell lines.
    Nabhan C; Gajria D; Krett NL; Gandhi V; Ghias K; Rosen ST
    Mol Cancer Ther; 2002 Nov; 1(13):1221-7. PubMed ID: 12479703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of SRC tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells.
    Duxbury MS; Ito H; Zinner MJ; Ashley SW; Whang EE
    Clin Cancer Res; 2004 Apr; 10(7):2307-18. PubMed ID: 15073106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bortezomib is ineffective in an orthotopic mouse model of pancreatic adenocarcinoma.
    Märten A; Zeiss N; Serba S; Mehrle S; von Lilienfeld-Toal M; Schmidt J
    Mol Cancer Ther; 2008 Nov; 7(11):3624-31. PubMed ID: 19001444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gemcitabine combined with gum mastic causes potent growth inhibition and apoptosis of pancreatic cancer cells.
    Huang XY; Wang HC; Yuan Z; Li A; He ML; Ai KX; Zheng Q; Qin HL
    Acta Pharmacol Sin; 2010 Jun; 31(6):741-5. PubMed ID: 20523344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapy in the A549 non-small-cell lung cancer cell line.
    Mortenson MM; Schlieman MG; Virudachalam S; Bold RJ
    Cancer Chemother Pharmacol; 2004 Oct; 54(4):343-53. PubMed ID: 15197486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular characterization of PS-341 (bortezomib) resistance: implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)-beta inhibitors.
    Hideshima T; Chauhan D; Ishitsuka K; Yasui H; Raje N; Kumar S; Podar K; Mitsiades C; Hideshima H; Bonham L; Munshi NC; Richardson PG; Singer JW; Anderson KC
    Oncogene; 2005 Apr; 24(19):3121-9. PubMed ID: 15735676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Mechanism of SPARC-enhanced chemosensitivity of pancreatic cancer cells to gemcitabine].
    Zhang J; Jiang H; Mao Z; Wang X; Fan X; Liu Y; Wang Y
    Zhonghua Zhong Liu Za Zhi; 2014 May; 36(5):335-40. PubMed ID: 25030587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. {Gamma}-tocotrienol inhibits pancreatic tumors and sensitizes them to gemcitabine treatment by modulating the inflammatory microenvironment.
    Kunnumakkara AB; Sung B; Ravindran J; Diagaradjane P; Deorukhkar A; Dey S; Koca C; Yadav VR; Tong Z; Gelovani JG; Guha S; Krishnan S; Aggarwal BB
    Cancer Res; 2010 Nov; 70(21):8695-705. PubMed ID: 20864511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MSX2 overexpression inhibits gemcitabine-induced caspase-3 activity in pancreatic cancer cells.
    Hamada S; Satoh K; Kimura K; Kanno A; Masamune A; Shimosegawa T
    World J Gastroenterol; 2005 Nov; 11(43):6867-70. PubMed ID: 16425399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Schedule-dependent molecular effects of the proteasome inhibitor bortezomib and gemcitabine in pancreatic cancer.
    Fahy BN; Schlieman MG; Virudachalam S; Bold RJ
    J Surg Res; 2003 Jul; 113(1):88-95. PubMed ID: 12943815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Apoptosis of myeloid leukemia cell line HL60 induced by Bortezomib, a proteasome inhibitor].
    Fu YB; Sun QX; Meng FY; Xie J; Zhou GB
    Zhonghua Yi Xue Za Zhi; 2006 Sep; 86(34):2413-6. PubMed ID: 17156654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.